Precision oncology software company GenomOncology announced on Thursday that it has entered into co-marketing partnership with Pillar Biosciences, a developer of next-generation sequencing (NGS) testing solutions.

This collaboration will integrate GenomOncology's clinical decision support platform with Pillar's research-use-only (RUO) targeted NGS panels to enable healthcare providers with comprehensive workflows to advance personalised cancer insights.

The aim is to provide personalised and effective cancer treatment guidance by integrating genomic data through GenomOncology's Pathology Workbench reporting, enabling a seamless workflow from the NGS sequencer to the report.

Garreth Hippe, GenomOncology's chief commercial officer, said: "Partnering with Pillar Biosciences will allow us to enhance our offering and provide clinicians with an integrated, data-driven sample to answer approach to precision cancer management. This collaboration enables us to provide more comprehensive, actionable insights for cancer care, empowering healthcare providers to make better, more informed decisions."